Advertisement

Setting Specifications for Drug Substances

  • Jon V. BeamanEmail author
Chapter
Part of the Biotechnology: Pharmaceutical Aspects book series (PHARMASP, volume XII)

Abstract

This article discusses the purpose of a drug substance specification and the variety of tests to be considered for inclusion. The relevance of these aspects to stability studies is examined and the differences between release testing and tests relevant to stability studies are explored. A scientific approach to setting drug substance specifications and to designing stability studies is encouraged and where necessary, the regulatory landscape is compared and contrasted to this approach.

Keywords

Drug Product Stability Study Drug Substance Acceptance Criterion Active Pharmaceutical Ingredient 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

References

  1. Carstensen T, Morris T (1993) Chemical stability of indomethacin in the solid amorphous and molten states. J Pharm Sci 82:657–659CrossRefPubMedGoogle Scholar
  2. Hancock BC, Zografi G (1997) Characteristics and significance of the amorphous state in pharmaceutical systems. J Pharm Sci 86(1):1–12CrossRefPubMedGoogle Scholar
  3. Humera A, Buckton G, Rawlins DA (1996) The use of isothermal microcalorimetry in the study of small degrees of amorphous content of a hydrophobic powder. Int J Pharm 130:195–201CrossRefGoogle Scholar
  4. Snorek SM, Bauer JF, Chidambaram N, Doub WH, Duffy EP, Etzler FM, Kelly RN, Lane JJ, Mueller RL, Prasanna HR, Pujara CP, Reif VD, Scarlett B, Stowell JG, Toma PH (2007) PQRI Recommendations on particle-size analysis of drug substances used in oral dosage forms. J Pharm Sci 96(6):1451–1467CrossRefPubMedGoogle Scholar
  5. Nichols G, Byard S, Bloxham MJ, Botterill J, Dawson NJ, Dennis A, Diart V, North NC, Sherwood JD (2002) A review of the terms agglomerate and aggregate with a recommendation for nomenclature used in powder and particle characterization. J Pharm Sci 91(10):2103–2109CrossRefPubMedGoogle Scholar
  6. Waterman KC, Carella AJ, Gumkowski MJ, Lukulay P, Macdonald BC, Roy MC, Shamblin SL (2007) Improved protocol and data analysis for accelerated shelf-life estimation of solid dosage forms. Pharm Res 24(4):780–790CrossRefPubMedGoogle Scholar

Copyright information

© American Association of Pharmaceutical Scientists 2010

Authors and Affiliations

  1. 1.Pfizer Global Research and DevelopmentKentUK

Personalised recommendations